425 related articles for article (PubMed ID: 23075894)
21. Immunocytochemical panel for distinguishing between carcinoma and reactive mesothelial cells in body cavity fluids.
Politi E; Kandaraki C; Apostolopoulou C; Kyritsi T; Koutselini H
Diagn Cytopathol; 2005 Mar; 32(3):151-5. PubMed ID: 15690338
[TBL] [Abstract][Full Text] [Related]
22. Calretinin, thrombomodulin, CEA, and CD15: a useful combination of immunohistochemical markers for differentiating pleural epithelial mesothelioma from peripheral pulmonary adenocarcinoma.
Comin CE; Novelli L; Boddi V; Paglierani M; Dini S
Hum Pathol; 2001 May; 32(5):529-36. PubMed ID: 11381372
[TBL] [Abstract][Full Text] [Related]
23. [Significance of combining detection of E-cadherin, carcinoembryonic antigen, and calretinin in cytological differential diagnosis of serous effusion].
Su XY; Li GD; Liu HB; Jiang LL
Ai Zheng; 2004 Oct; 23(10):1185-9. PubMed ID: 15473932
[TBL] [Abstract][Full Text] [Related]
24. CK5/6 in effusions: no difference between mesothelioma and pulmonary and nonpulmonary adenocarcinoma.
Dejmek A
Acta Cytol; 2008; 52(5):579-83. PubMed ID: 18833821
[TBL] [Abstract][Full Text] [Related]
25. Podoplanin is a better immunohistochemical marker for sarcomatoid mesothelioma than calretinin.
Padgett DM; Cathro HP; Wick MR; Mills SE
Am J Surg Pathol; 2008 Jan; 32(1):123-7. PubMed ID: 18162779
[TBL] [Abstract][Full Text] [Related]
26. D2-40: a reliable marker in the diagnosis of pleural mesothelioma.
Müller AM; Franke FE; Müller KM
Pathobiology; 2006; 73(1):50-4. PubMed ID: 16785767
[TBL] [Abstract][Full Text] [Related]
27. The application of immunocytochemistry to direct smears in the diagnosis of effusions.
Knoepp SM; Placido J; Fields KL; Thomas D; Roh MH
Diagn Cytopathol; 2013 May; 41(5):425-30. PubMed ID: 22549950
[TBL] [Abstract][Full Text] [Related]
28. The value of anti-calretinin antibody in the differential diagnosis of normal and reactive mesothelia versus metastatic tumors in effusion cytology.
Nagel H; Hemmerlein B; Ruschenburg I; Hüppe K; Droese M
Pathol Res Pract; 1998; 194(11):759-64. PubMed ID: 9842634
[TBL] [Abstract][Full Text] [Related]
29. Differentiation of mesothelioma from adenocarcinoma in serous effusions: the role of hyaluronic acid and CD44 localization.
Afify AM; Stern R; Michael CW
Diagn Cytopathol; 2005 Mar; 32(3):145-50. PubMed ID: 15690337
[TBL] [Abstract][Full Text] [Related]
30. Claudin-4 immunohistochemistry is highly effective in distinguishing adenocarcinoma from malignant mesothelioma in effusion cytology.
Jo VY; Cibas ES; Pinkus GS
Cancer Cytopathol; 2014 Apr; 122(4):299-306. PubMed ID: 24421209
[TBL] [Abstract][Full Text] [Related]
31. Utility of MOC-31 monoclonal antibody in differentiating metastatic adenocarcinoma cells and reactive mesothelial cells in effusion cytology.
Patil B; Shivkumar V; Gangane N
Indian J Pathol Microbiol; 2018; 61(1):90-93. PubMed ID: 29567891
[TBL] [Abstract][Full Text] [Related]
32. Use of a panel of markers in the differential diagnosis of adenocarcinoma and reactive mesothelial cells in fluid cytology.
Ko EC; Jhala NC; Shultz JJ; Chhieng DC
Am J Clin Pathol; 2001 Nov; 116(5):709-15. PubMed ID: 11710688
[TBL] [Abstract][Full Text] [Related]
33. MOC-31 aids in the differentiation between adenocarcinoma and reactive mesothelial cells.
Morgan RL; De Young BR; McGaughy VR; Niemann TH
Cancer; 1999 Dec; 87(6):390-4. PubMed ID: 10603193
[TBL] [Abstract][Full Text] [Related]
34. Value of calretinin immunostaining in differentiating epithelial mesothelioma from lung adenocarcinoma.
Ordóñez NG
Mod Pathol; 1998 Oct; 11(10):929-33. PubMed ID: 9796717
[TBL] [Abstract][Full Text] [Related]
35. Value of the mesothelium-associated antibodies thrombomodulin, cytokeratin 5/6, calretinin, and CD44H in distinguishing epithelioid pleural mesothelioma from adenocarcinoma metastatic to the pleura.
Cury PM; Butcher DN; Fisher C; Corrin B; Nicholson AG
Mod Pathol; 2000 Feb; 13(2):107-12. PubMed ID: 10697265
[TBL] [Abstract][Full Text] [Related]
36. Monoclonal antibody MOC-31 reactivity as a marker for adenocarcinoma in cytologic preparations.
Hecht JL; Pinkus JL; Pinkus GS
Cancer; 2006 Feb; 108(1):56-9. PubMed ID: 16329115
[TBL] [Abstract][Full Text] [Related]
37. Calretinin staining pattern aids in the differentiation of mesothelioma from adenocarcinoma in serous effusions.
Chhieng DC; Yee H; Schaefer D; Cangiarella JF; Jagirdar J; Chiriboga LA; Jagirdar J; Chiriboga LA; Cohen JM
Cancer; 2000 Jun; 90(3):194-200. PubMed ID: 10896333
[TBL] [Abstract][Full Text] [Related]
38. The value of ThinPrep and cytospin preparation in pleural effusion cytological diagnosis of mesothelioma and adenocarcinoma.
Ylagan LR; Zhai J
Diagn Cytopathol; 2005 Mar; 32(3):137-44. PubMed ID: 15690333
[TBL] [Abstract][Full Text] [Related]
39. The use of immunohistochemistry to distinguish reactive mesothelial cells from malignant mesothelioma in cytologic effusions.
Hasteh F; Lin GY; Weidner N; Michael CW
Cancer Cytopathol; 2010 Apr; 118(2):90-6. PubMed ID: 20209622
[TBL] [Abstract][Full Text] [Related]
40. Scoring system for differential diagnosis of malignant mesothelioma and reactive mesothelial cells on cytology specimens.
Kimura N; Dota K; Araya Y; Ishidate T; Ishizaka M
Diagn Cytopathol; 2009 Dec; 37(12):885-90. PubMed ID: 19572412
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
